Home › Employers › Visby Medical, Inc.
Visby Medical, Inc.: H-1B salaries and sponsorship
Visby Medical, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 3. Median offered salary: $157,414.
Does Visby Medical, Inc. sponsor H-1B visas?
Visby Medical, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Dec 9, 2024. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.
Salaries by job title
| Job title | LCAs | Median salary |
|---|---|---|
| Process and Controls Transformation Management Analyst | 1 | $145,600 |
| Enterprise Systems Architect | 1 | $175,215 |
| Sr. Manager, R&D Finance | 1 | $157,414 |
Applications by fiscal year
| Fiscal year | LCAs | Median salary |
|---|---|---|
| FY2023 | 1 | $145,600 |
| FY2024 | 1 | $175,215 |
| FY2025 | 1 | $157,414 |
Prevailing wage levels
The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.
Where the jobs are
Occupations
Latest applications
| Job title | Base salary | Location | Submitted | Start date | Status |
|---|---|---|---|---|---|
| Sr. Manager, R&D Finance | $157,414 Level III | San Jose, CA | Dec 9, 2024 | Jan 18, 2025 | Certified |
| Enterprise Systems Architect | $175,215 Level III | San Jose, CA | Nov 27, 2023 | May 12, 2024 | Certified |
| Process and Controls Transformation Management Analyst | $145,600 Level III | San Jose, CA | Mar 10, 2023 | Mar 29, 2023 | Certified |
Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).